Results 191 to 198 of about 19,211 (198)

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis

Genetics in Medicine, 2005
Jon Emery, Julian Pt Higgins, Simon Sanderson   +2 more
exaly  

CYP2C9 Genotype‐Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R‐ and S‐Warfarin and Their Oxidative Metabolites

Journal of Clinical Pharmacology, 2017
Allan E Rettie
exaly  

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects

European Journal of Clinical Pharmacology, 2003
Iga Tatsuji, Horiuchi Ryuya, Yamamoto Koujirou   +2 more
exaly  

CYP2C9

openaire   +1 more source

Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes

Pharmacogenomics Journal, 2003
Paul Ho, Ulrich M Zanger, Frank S Abbott   +2 more
exaly  

CYP2C9 allelic variants: ethnic distribution and functional significance

Advanced Drug Delivery Reviews, 2002
Richard Kim, , C Michael Stein
exaly  

No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3

European Journal of Clinical Pharmacology, 2003
Junichi Azuma, Tsuyoshi Fukuda, Yoshihiko Funae   +2 more
exaly  

CYP2C9 BINDING MODELS

2005
KOCHER JEAN-PIERRE, EWING TODD J A, KORZEKWA KENNETH R   +2 more
openaire   +1 more source